- Conditions
- Solid Tumors
- Interventions
- Epacadostat, Nivolumab, Ipilimumab, Lirilumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 16,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Muscle Loss, Muscle Anabolism, Muscle Performance
- Interventions
- Leucine-enriched nutritional supplement, Placebo
- Other
- Lead sponsor
- United States Army Research Institute of Environmental Medicine
- Federal
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Natick, Massachusetts
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Casdozokitug, Atezolizumab, Bevacizumab, Placebo
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more
- Conditions
- Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
- Interventions
- Nivolumab, Cabozantinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
- Drug · Device
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2038
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatoid Arthritis
- Interventions
- natalizumab, placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Escondido, California + 7 more
- Conditions
- Gastroparesis
- Interventions
- GI Neuromodulation, Immunotherapy, Pyloric Therapies
- Device · Drug · Procedure
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- Not listed
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Glioblastoma
- Interventions
- DSP-7888 Dosing Emulsion, Bevacizumab
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 30 more
- Conditions
- Fanconi Anemia
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, fludarabine phosphate, methylprednisolone, Hematopoietic stem cell transplantation
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 44 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Retinopathy of Prematurity (ROP)
- Interventions
- 1% phenylephrine and 0.2% cyclopentolate
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Bone Infection, Osteomyelitis, Septic Arthritis, Joint Infection, Prosthetic Joint Infection
- Interventions
- Dalbavancin, Vancomycin
- Drug
- Lead sponsor
- Infectious Diseases Physicians, Inc.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Annandale, Virginia
- Conditions
- Chronic Heart Failure, Pulmonary Disorder, Chronic Obstructive
- Interventions
- sip feeding with stable isotope infusion
- Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Cetuximab, Ulixertinib, Encorafenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab, celecoxib, proteomic profiling, immunohistochemistry staining method, laboratory biomarker analysis, mass spectrometry
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hemophilia B
- Interventions
- AAV5-hFIXco-Padua, Factor IX (FIX)
- Genetic · Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
- Conditions
- Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
- Interventions
- Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
- Drug
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
- Conditions
- PCV, Polypoidal Choroidal Vasculopathy
- Interventions
- high-dose ranibizumab, ranibizumab
- Drug
- Lead sponsor
- Hawaii Pacific Health
- Other
- Eligibility
- 25 Years to 95 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Honolulu, Hawaii • ‘Aiea, Hawaii
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab emtansine, Treatment of physician's choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 59
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Cyclosporins, nab-paclitaxel
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Von Willebrand Disease, Type 3
- Interventions
- Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more
- Conditions
- HLA-A2 Positive Cells Present, Refractory Melanoma
- Interventions
- Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor, PD1 Inhibitor, Recombinant Interferon Alfa-2b, Rintatolimod
- Biological · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hypertension
- Interventions
- Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- USA, New Jersey
- Conditions
- Graft vs Host Disease, Multiple Myeloma
- Interventions
- Myeloma Immunoglobulin Idiotype Vaccine-KLH, GM-CSF
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Piflufolastat F 18 Intravenous Solution [PYLARIFY]
- Drug
- Lead sponsor
- Lantheus Medical Imaging
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Irvine, California • Los Angeles, California + 11 more